Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 7/10

vs
industry
vs
history
Cash to Debt No Debt
CYBX's Cash to Debt is ranked higher than
97% of the 377 Companies
in the Global Medical Devices industry.

( Industry Median: 6.28 vs. CYBX: No Debt )
CYBX' s 10-Year Cash to Debt Range
Min: 0.64   Max: 25573
Current: No Debt

0.64
25573
Equity to Asset 0.89
CYBX's Equity to Asset is ranked higher than
93% of the 358 Companies
in the Global Medical Devices industry.

( Industry Median: 0.64 vs. CYBX: 0.89 )
CYBX' s 10-Year Equity to Asset Range
Min: -0.14   Max: 0.94
Current: 0.89

-0.14
0.94
Interest Coverage 658.37
CYBX's Interest Coverage is ranked higher than
70% of the 223 Companies
in the Global Medical Devices industry.

( Industry Median: 205.72 vs. CYBX: 658.37 )
CYBX' s 10-Year Interest Coverage Range
Min: 5.59   Max: 9999.99
Current: 658.37

5.59
9999.99
F-Score: 4
Z-Score: 37.36
M-Score: -2.51
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 5/10

vs
industry
vs
history
Operating margin (%) 30.81
CYBX's Operating margin (%) is ranked higher than
97% of the 366 Companies
in the Global Medical Devices industry.

( Industry Median: 6.25 vs. CYBX: 30.81 )
CYBX' s 10-Year Operating margin (%) Range
Min: -1625   Max: 30.81
Current: 30.81

-1625
30.81
Net-margin (%) 18.23
CYBX's Net-margin (%) is ranked higher than
92% of the 366 Companies
in the Global Medical Devices industry.

( Industry Median: 4.82 vs. CYBX: 18.23 )
CYBX' s 10-Year Net-margin (%) Range
Min: -1475   Max: 46.76
Current: 18.23

-1475
46.76
ROE (%) 20.19
CYBX's ROE (%) is ranked higher than
96% of the 365 Companies
in the Global Medical Devices industry.

( Industry Median: 5.79 vs. CYBX: 20.19 )
CYBX' s 10-Year ROE (%) Range
Min: -1275.79   Max: 109.46
Current: 20.19

-1275.79
109.46
ROA (%) 17.56
CYBX's ROA (%) is ranked higher than
98% of the 380 Companies
in the Global Medical Devices industry.

( Industry Median: 3.09 vs. CYBX: 17.56 )
CYBX' s 10-Year ROA (%) Range
Min: -258.97   Max: 50.36
Current: 17.56

-258.97
50.36
ROC (Joel Greenblatt) (%) 110.07
CYBX's ROC (Joel Greenblatt) (%) is ranked higher than
98% of the 379 Companies
in the Global Medical Devices industry.

( Industry Median: 12.55 vs. CYBX: 110.07 )
CYBX' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -3466.67   Max: 110.07
Current: 110.07

-3466.67
110.07
Revenue Growth (%) 15.80
CYBX's Revenue Growth (%) is ranked higher than
90% of the 278 Companies
in the Global Medical Devices industry.

( Industry Median: 5.40 vs. CYBX: 15.80 )
CYBX' s 10-Year Revenue Growth (%) Range
Min: 1.5   Max: 180.6
Current: 15.8

1.5
180.6
EBITDA Growth (%) 24.80
CYBX's EBITDA Growth (%) is ranked higher than
93% of the 249 Companies
in the Global Medical Devices industry.

( Industry Median: -3.70 vs. CYBX: 24.80 )
CYBX' s 10-Year EBITDA Growth (%) Range
Min: -54.6   Max: 24.8
Current: 24.8

-54.6
24.8
EPS Growth (%) -15.30
CYBX's EPS Growth (%) is ranked higher than
63% of the 233 Companies
in the Global Medical Devices industry.

( Industry Median: -2.80 vs. CYBX: -15.30 )
CYBX' s 10-Year EPS Growth (%) Range
Min: -38.2   Max: 12.1
Current: -15.3

-38.2
12.1
» CYBX's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q1 2013

CYBX Guru Trades in Q1 2013

Steven Cohen 111,589 sh (+428.36%)
Paul Tudor Jones 18,400 sh (+253.85%)
Joel Greenblatt 13,195 sh (+113.1%)
Jim Simons 1,955,500 sh (+5.91%)
RS Investment Management 645,847 sh (+0.38%)
John Hussman 898,000 sh (-9.93%)
» More
Q2 2013

CYBX Guru Trades in Q2 2013

Steven Cohen 150,603 sh (+34.96%)
Jim Simons 2,325,394 sh (+18.92%)
Joel Greenblatt 10,070 sh (-23.68%)
RS Investment Management 464,958 sh (-28.01%)
John Hussman 522,000 sh (-41.87%)
Paul Tudor Jones 6,200 sh (-66.3%)
» More
Q3 2013

CYBX Guru Trades in Q3 2013

RS Investment Management 612,956 sh (+31.83%)
Paul Tudor Jones 7,000 sh (+12.9%)
Steven Cohen 165,798 sh (+10.09%)
Jim Simons 2,465,894 sh (+6.04%)
John Hussman 509,000 sh (-2.49%)
Joel Greenblatt 7,383 sh (-26.68%)
» More
Q4 2013

CYBX Guru Trades in Q4 2013

RS Investment Management 912,588 sh (+48.88%)
Paul Tudor Jones Sold Out
Jim Simons 2,310,094 sh (-6.32%)
John Hussman 355,000 sh (-30.26%)
Joel Greenblatt 5,079 sh (-31.21%)
Steven Cohen 11,957 sh (-92.79%)
» More
» Details

Insider Trades

Latest Guru Trades with CYBX

GuruDate Trades Impact to Portfolio Price Range * (?) Current Price Change from Average Current Shares
John Hussman 2013-12-31 Reduce -30.26%0.42%$50.84 - $71.5 $ 62.022%355000
Joel Greenblatt 2013-12-31 Reduce -31.21%$50.84 - $71.5 $ 62.022%5079
Joel Greenblatt 2013-09-30 Reduce -26.68%0.01%$50.51 - $56 $ 62.0218%7383
John Hussman 2013-06-30 Reduce -41.87%0.63%$42.97 - $52.54 $ 62.0231%522000
Joel Greenblatt 2013-06-30 Reduce -23.68%0.01%$42.97 - $52.54 $ 62.0231%10070
Joel Greenblatt 2013-03-31 Add 113.1%0.02%$42.73 - $55.42 $ 62.0230%13195
Joel Greenblatt 2012-12-31 New Buy0.02%$44.5 - $53.23 $ 62.0224%6192
Joel Greenblatt 2012-03-31 Sold Out 0.05%$32.18 - $39.01 $ 62.0290%0
Joel Greenblatt 2011-12-31 Reduce -24.38%0.02%$26.93 - $34.2 $ 62.02109%12604
Carl Icahn 2011-09-30 Sold Out 0.98%$23.7 - $30 $ 62.02127%0
Joel Greenblatt 2011-09-30 Add 27.85%0.02%$23.7 - $30 $ 62.02127%16667
Joel Greenblatt 2011-06-30 Reduce -23.28%0.04%$24.94 - $35.59 $ 62.0299%13036
John Hussman 2011-03-31 New Buy0.53%$30.66 - $34.96 $ 62.0288%1000000
Joel Greenblatt 2011-03-31 New Buy0.16%$30.66 - $34.96 $ 62.0288%16992
Premium More recent guru trades are included for Premium Members only!!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/E(ttm) 35.90
CYBX's P/E(ttm) is ranked lower than
52% of the 231 Companies
in the Global Medical Devices industry.

( Industry Median: 26.70 vs. CYBX: 35.90 )
CYBX' s 10-Year P/E(ttm) Range
Min: 6.15   Max: 219.29
Current: 35.9

6.15
219.29
P/B 6.80
CYBX's P/B is ranked lower than
72% of the 355 Companies
in the Global Medical Devices industry.

( Industry Median: 3.20 vs. CYBX: 6.80 )
CYBX' s 10-Year P/B Range
Min: 3.92   Max: 180.33
Current: 6.8

3.92
180.33
P/S 6.20
CYBX's P/S is ranked lower than
71% of the 372 Companies
in the Global Medical Devices industry.

( Industry Median: 2.74 vs. CYBX: 6.20 )
CYBX' s 10-Year P/S Range
Min: 2.16   Max: 10.82
Current: 6.2

2.16
10.82
PFCF 43.70
CYBX's PFCF is ranked lower than
60% of the 179 Companies
in the Global Medical Devices industry.

( Industry Median: 27.48 vs. CYBX: 43.70 )
CYBX' s 10-Year PFCF Range
Min: 10   Max: 1235.33
Current: 43.7

10
1235.33
EV-to-EBIT 20.40
CYBX's EV-to-EBIT is ranked higher than
62% of the 293 Companies
in the Global Medical Devices industry.

( Industry Median: 20.91 vs. CYBX: 20.40 )
CYBX' s 10-Year EV-to-EBIT Range
Min: 12.3   Max: 309.6
Current: 20.4

12.3
309.6
PEG 1.50
CYBX's PEG is ranked higher than
84% of the 119 Companies
in the Global Medical Devices industry.

( Industry Median: 2.53 vs. CYBX: 1.50 )
CYBX' s 10-Year PEG Range
Min: 0.74   Max: 1.92
Current: 1.5

0.74
1.92
Shiller P/E 38.10
CYBX's Shiller P/E is ranked lower than
54% of the 141 Companies
in the Global Medical Devices industry.

( Industry Median: 27.00 vs. CYBX: 38.10 )
CYBX' s 10-Year Shiller P/E Range
Min: 33.07   Max: 214.29
Current: 38.1

33.07
214.29

Valuation & Return

vs
industry
vs
history
Price/Net Cash 19.00
CYBX's Price/Net Cash is ranked lower than
63% of the 119 Companies
in the Global Medical Devices industry.

( Industry Median: 14.30 vs. CYBX: 19.00 )
CYBX' s 10-Year Price/Net Cash Range
Min: 5.63   Max: 136.76
Current: 19

5.63
136.76
Price/Net Current Asset Value 13.00
CYBX's Price/Net Current Asset Value is ranked lower than
57% of the 174 Companies
in the Global Medical Devices industry.

( Industry Median: 9.10 vs. CYBX: 13.00 )
CYBX' s 10-Year Price/Net Current Asset Value Range
Min: 5.26   Max: 675
Current: 13

5.26
675
Price/Tangible Book 7.30
CYBX's Price/Tangible Book is ranked lower than
70% of the 328 Companies
in the Global Medical Devices industry.

( Industry Median: 4.40 vs. CYBX: 7.30 )
CYBX' s 10-Year Price/Tangible Book Range
Min: 2.02   Max: 178.58
Current: 7.3

2.02
178.58
Price/DCF (Projected) 2.10
CYBX's Price/DCF (Projected) is ranked higher than
56% of the 177 Companies
in the Global Medical Devices industry.

( Industry Median: 1.90 vs. CYBX: 2.10 )
CYBX' s 10-Year Price/DCF (Projected) Range
Min: 1.73   Max: 93.7
Current: 2.1

1.73
93.7
Price/Median PS Value 1.30
CYBX's Price/Median PS Value is ranked lower than
52% of the 338 Companies
in the Global Medical Devices industry.

( Industry Median: 1.10 vs. CYBX: 1.30 )
CYBX' s 10-Year Price/Median PS Value Range
Min: 0.53   Max: 35.23
Current: 1.3

0.53
35.23
Price/Peter Lynch Fair Value 1.70
CYBX's Price/Peter Lynch Fair Value is ranked higher than
69% of the 59 Companies
in the Global Medical Devices industry.

( Industry Median: 1.80 vs. CYBX: 1.70 )
CYBX' s 10-Year Price/Peter Lynch Fair Value Range
Min: 1.05   Max: 30.09
Current: 1.7

1.05
30.09
Price/Graham Number 3.40
CYBX's Price/Graham Number is ranked lower than
60% of the 213 Companies
in the Global Medical Devices industry.

( Industry Median: 2.40 vs. CYBX: 3.40 )
CYBX' s 10-Year Price/Graham Number Range
Min: 1.05   Max: 10.89
Current: 3.4

1.05
10.89
Earnings Yield (Greenblatt) 4.90
CYBX's Earnings Yield (Greenblatt) is ranked higher than
69% of the 279 Companies
in the Global Medical Devices industry.

( Industry Median: 4.60 vs. CYBX: 4.90 )
CYBX' s 10-Year Earnings Yield (Greenblatt) Range
Min: 0.3   Max: 8.1
Current: 4.9

0.3
8.1
Forward Rate of Return (Yacktman) 23.56
CYBX's Forward Rate of Return (Yacktman) is ranked higher than
95% of the 259 Companies
in the Global Medical Devices industry.

( Industry Median: 1.31 vs. CYBX: 23.56 )
CYBX' s 10-Year Forward Rate of Return (Yacktman) Range
Min: -8.1   Max: 37.9
Current: 23.56

-8.1
37.9

Business Description

Industry: Medical Devices » Medical Devices
Compare:MDT, SYK, SMA, ZMH, STJ » details
Traded in other countries:JC8.Germany
Cyberonics, Inc. was incorporated in the state of Delaware in 1987. The Company is a medical device company. It is engaged in the design, development, sales and marketing of implantable medical devices that provide a unique therapy, vagus nerve stimulation therapy (VNS Therapy), for the treatment of refractory epilepsy and treatment-resistant depression. The Company's proprietary VNS Therapy System includes: An implantable pulse generator to provide stimulation to the vagus nerve; A lead that connects the generator to the vagus nerve; Equipment to assist with the implant procedure; Equipment to assist the treating physician with setting the stimulation parameters for each patient; Instruction manuals; and Magnets to temporarily suspend or induce stimulation manually. The VNS Therapy pulse generator and lead are surgically implanted into patients generally during an outpatient procedure. The battery contained in the generator has a finite life, which varies according to the model as well as the stimulation parameters for each patient. At or near the end of the useful life of a battery, a patient may, with the advice of a physician, choose to implant a new generator, which may be done with or without replacing the original lead. The Company sells the VNS Therapy System to hospitals and ambulatory surgery centers ('ASCs') on payment terms that are generally 30 days from the shipment date. The Company's medical devices are subject to regulation by numerous government agencies, including the FDA and comparable foreign agencies.

Personalized Checklist








Within your circle of competence?
Macro economic environment favorable?
High quality business?
Enough margin of safety with stocks?
Gurus are buying?
Insiders are buying?
Management capable and shareholder friendly?
Catalyst for stock price to appreciate?
Your level of confidence with the research?

Add Notes, Comments or Ask Questions

User Comments

No comment yet

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Free 7-day Trial
FEEDBACK
Hide